Latest AI and machine learning research in skin cancer for healthcare professionals.
BACKGROUND: The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic agents repres...
Messenger RNA-lipid nanoparticle (mRNA-LNP) therapeutics have emerged as a versatile drug modality, ...
BACKGROUND: Regulated cell death programs influence melanoma progression and antitumor immunity, yet...
Liver cancer remains a major global health burden, with hepatocellular carcinoma (HCC) and intrahepa...
Oncolytic viruses (OVs) represent a versatile platform for cancer immunotherapy, capable of selectiv...
The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of m...
OBJECTIVE: Lung adenocarcinoma (LUAD) molecular heterogeneity limits traditional prognostic models. ...
Metastatic renal cell carcinoma remains clinically challenging because of heterogeneous outcomes and...
PURPOSE: Antibody-drug conjugates (ADC) targeting trophoblast cell surface antigen 2 (TROP-2) and cM...
Artificial intelligence (AI) has moved from proof-of-concept studies in dermatology to selective, re...
Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian p...
Myeloid cells-including macrophages, monocytes, neutrophils and dendritic cells-are metabolically pl...
BACKGROUND: ∼60%-70% of patients with metastatic non-small cell lung cancer (NSCLC) have relatively ...
Artificial intelligence (AI) in dermatology has moved beyond the early paradigm of single-image clas...
Deoxynivalenol (DON) has been reported to exhibit skin toxicity and carcinogenic potential; however,...
This study aims to identify a prognostic gene signature associated with cell pyroptosis and skin cut...
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with high metastatic pote...
Endometrial cancer (EC) is the most common gynaecological malignancy worldwide, yet the prognosis fo...
Malignant tumors, including osteosarcoma (OS), are major non-communicable chronic diseases driven by...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a five-year survival ...
Neoantigens are critical targets for cancer immunotherapy, yet the relationship between experimental...